# US 2022/0033793 A1 · Novel crispr dna targeting enzymes and systems

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0033793 A1
- Document ID: US20220033793A1
- Status: Published application
- Kind: A1
- Application number: 17/505,578
- Filed: 2021-10-19
- Published: 2022-02-03
- Earliest claimed: 2019-09-09
- Assignees: Arbor Biotechnologies, Inc.
- Applicants: Arbor Biotechnologies, Inc.
- Inventors: David A. Scott; David R. Cheng; Winston X. Yan; Tia M. DiTommaso
- Web page: https://patentgrep.com/patent/US20220033793A1

## CPC

- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/102: {Mutagenizing nucleic acids}
- C12N 1/20: Bacteria; Culture media therefor
- C12N 5/0687: {Renal stem cells; Renal progenitors}
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 15/63: Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N 15/70: Vectors or expression systems specially adapted for E. coli
- C12N 15/85: for animal cells
- C12N 15/907: {in mammalian cells}
- C12Q 1/6823: Release of bound markers
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2800/10: Plasmid DNA
- C12N 2800/80: Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The disclosure describes novel systems, methods, and compositions for the manipulation of nucleic acids in a targeted fashion. The disclosure describes non-naturally occurring, engineered CRISPR systems, components, and methods for targeted modification of nucleic acids. Each system includes one or more protein components and one or more nucleic acid components that together target nucleic acids.

## Claims

### Claim 1

An engineered, non-naturally occurring Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated (Cas) system comprising:
(a) an RNA guide or a nucleic acid encoding the RNA guide, wherein the RNA guide comprises a direct repeat sequence and a spacer sequence; and
(b) a CRISPR-Cas effector protein or a nucleic acid encoding the CRISPR-Cas effector protein, wherein the CRISPR-Cas effector protein comprises the amino acid sequence set forth in SEQ ID NO: 4,
wherein the CRISPR-Cas effector protein binds to the RNA guide, and wherein the spacer sequence binds to a target nucleic acid.

### Claim 2 (depends on 1)

The system of claim 1, wherein the direct repeat sequence comprises a nucleotide sequence with at least 95% sequence identity to
(SEQ ID NO: 291)
CCUGUUGUGAAUACUCUUUUAUAGGUAUCAAACAAC.

### Claim 3 (depends on 2)

The system of claim 2, wherein the direct repeat sequence comprises a nucleotide sequence set forth in SEQ ID NO: 291.

### Claim 4 (depends on 1)

The system of claim 1, wherein the spacer sequence comprises between 15 and 55 nucleotides in length.

### Claim 5 (depends on 4)

The system of claim 4, wherein the spacer sequence comprises between 20 and 45 nucleotides in length.

### Claim 6 (depends on 1)

The system of claim 1, wherein the target nucleic acid comprises a sequence complementary to a nucleotide sequence in the spacer sequence.

### Claim 7 (depends on 1)

The system of claim 1, wherein the system does not include a tracrRNA.

### Claim 8 (depends on 1)

The system of claim 1, wherein the CRISPR-Cas effector protein recognizes a protospacer adjacent motif (PAM) sequence, wherein the PAM sequence comprises a nucleotide sequence set forth as 5′-NTTN-3′, 5′-NTTR-3′, or 5′-NNR-3′, wherein “N” is any nucleotide and “R” is A or G.

### Claim 9 (depends on 1)

The system of claim 1, wherein the CRISPR-Cas effector protein further comprises at least one nuclear localization signal (NLS), at least one nuclear export signal (NES), or at least one NLS and at least one NES.

### Claim 10 (depends on 1)

The system of claim 1, wherein the CRISPR-Cas effector protein further comprises a peptide tag, a fluorescent protein, a base-editing domain, a DNA methylation domain, a histone residue modification domain, a localization factor, a transcription modification factor, a light-gated control factor, a chemically inducible factor, or a chromatin visualization factor.

### Claim 11 (depends on 1)

The system of claim 1, wherein the nucleic acid encoding the CRISPR-Cas effector protein is codon-optimized for expression in a cell.

### Claim 12 (depends on 1)

The system of claim 1, wherein the nucleic acid encoding the CRISPR-Cas effector protein is operably linked to a promoter.

### Claim 13 (depends on 1)

The system of claim 1, wherein the nucleic acid encoding the CRISPR-Cas effector protein is in a vector.

### Claim 14 (depends on 13)

The system of claim 13, wherein the vector comprises a retroviral vector, a lentiviral vector, a phage vector, an adenoviral vector, an adeno-associated vector, or a herpes simplex vector.

### Claim 15 (depends on 1)

The system of claim 1, wherein the system is present in a delivery system comprising a nanoparticle, a liposome, an exosome, a microvesicle, or a gene-gun.

### Claim 16 (depends on 1)

A cell comprising the system of claim 1.

### Claim 17 (depends on 16)

The cell of claim 16, wherein the cell is a prokaryotic cell or a eukaryotic cell.

### Claim 18 (depends on 16)

The cell of claim 16, wherein the cell is a mammalian cell or a plant cell.

### Claim 19 (depends on 18)

The cell of claim 18, wherein the cell is a human cell.

### Claim 20 (depends on 1)

A method of binding the system of claim 1 to the target nucleic acid in a cell comprising:
(a) providing the system; and
(b) delivering the system to the cell,
wherein the cell comprises the target nucleic acid, wherein the CRISPR-Cas effector protein binds to the RNA guide, and wherein the spacer sequence binds to the target nucleic acid.

### Claim 21 (depends on 20)

The method of claim 20, wherein the target nucleic acid is a single-stranded DNA or a double-stranded DNA.

### Claim 22 (depends on 20)

The method of claim 20, wherein binding the system to the target nucleic acid results in cleavage of the target nucleic acid.

### Claim 23 (depends on 22)

The method of claim 22, wherein cleavage of the target nucleic acid results in formation of an insertion or a deletion in the target nucleic acid.
